Related Experiment Video
Updated: Feb 11, 2026
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Mary E Klein1, Marta Kovatcheva1, Lara E Davis2
1The Louis V. Gerstner Graduate School of Biomedical Sciences and the Sloan Kettering Institute Program in Molecular Biology, Memorial Sloan Kettering Cancer Center, RRL917C, Box 207, 1275 York Avenue, New York, NY 10065, USA.
Abstract:
CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many other combinations have recently entered clinical trials in multiple diseases. To achieve maximal benefit with CDK4/6 inhibitors it will be critical to understand the cellular mechanisms by which they act. Here we highlight the mechanisms by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing cytostatic growth arrest, and discuss how this knowledge may inform new combinations, improve outcomes, and modify dosing schedules in the future.
Insights
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors offer new therapeutic strategies. Understanding their anti-tumor mechanisms beyond cell cycle arrest is key to optimizing combinations and improving patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors represent a significant advancement in cancer therapy.
- Their efficacy is well-established in combination with hormone receptor antagonists for breast cancer treatment.
- Numerous clinical trials are exploring novel combinations across various diseases.
Purpose of the Study:
- To elucidate the cellular mechanisms of CDK4/6 inhibitors beyond cytostatic effects.
- To explore how understanding these mechanisms can guide future therapeutic strategies.
- To identify potential improvements in combination therapies, outcomes, and dosing schedules.
Main Methods:
- Literature review and analysis of existing preclinical and clinical data.
- Exploration of cellular pathways targeted by CDK4/6 inhibitors.
- Discussion of emerging research on CDK4/6 inhibitor mechanisms of action.
Main Results:
- CDK4/6 inhibitors exert anti-tumor effects through multiple mechanisms beyond cell cycle arrest.
- These mechanisms include modulation of tumor microenvironment and immune responses.
- Understanding these diverse actions is crucial for therapeutic development.
Conclusions:
- Further research into the multifaceted mechanisms of CDK4/6 inhibitors is warranted.
- This knowledge will facilitate the design of more effective combination therapies.
- Optimized treatment strategies may lead to improved patient outcomes and personalized dosing.
Related Concept Videos
01:28Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
01:23Local Anesthetics: Mechanism of Action
Local anesthetics are amphiphilic molecules consisting of a hydrophobic aromatic part linked to a hydrophilic group by an ester or amide linkage. They are weak bases and are usually available as salts, which increases their solubility and stability. Once administered, LAs exist in the body either...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:06Fixed Action Patterns